Background Clinical benefit from programmed cell death 1 receptor (PD-1) inhibitors relies on reinvigoration of endogenous antitumor immunity. Nonetheless, robust immunological markers, based on circulating immune cell subsets associated with therapeutic efficacy are yet to be validated. Methods We ...
Research Assistant
AI chat, annotations, notes & similar papers
No comments yet
Be the first to share your thoughts!